Ebpay生命医药出版社

Ebpay生命

102912

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.4 Breast Cancer (Dove Med Press)
  • 3.2 Clin Epidemiol
  • 2.6 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.7 Clin Interv Aging
  • 5.1 Drug Des Dev Ther
  • 3.1 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.6 Int J Women's Health
  • 2.9 Neuropsych Dis Treat
  • 2.8 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.2 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 3.0 Diabet Metab Synd Ob
  • 3.2 Psychol Res Behav Ma
  • 3.4 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.0 Risk Manag Healthc Policy
  • 4.1 J Inflamm Res
  • 2.0 Int J Gen Med
  • 3.4 J Hepatocell Carcinoma
  • 3.0 J Asthma Allergy
  • 2.2 Clin Cosmet Investig Dermatol
  • 2.4 J Multidiscip Healthc



更多详情 >>





已发表论文

纤维蛋白溶酶原激活抑制剂-1 (PAI-1 ) 和纤维蛋白溶酶原激活受体-1 (PAR-1 ) 的遗传多态性与接受盆腔放疗的中国直肠癌患者中的急性正常组织毒性相关

 

Authors Zhang H, Wang M, Shi T, Shen L, Zhu J, Sun M, Deng Y, Liang L, Li G, Wu Y, Fan M, Wei Q, Zhang Z
Received 28 February 2015
Accepted for publication 23 April 2015
Published 27 August 2015 Volume 2015:8 Pages 2291—2301
DOI http://dx.doi.org/10.2147/OTT.S83723
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication:  Dr William C Cho


Abstract: Plasminogen activator inhibitor type 1 (PAI-1) and protease-activated receptor-1 (PAR-1) are crucial mediators of the intestinal microenvironment and are involved in radiation-induced acute and chronic injury. To evaluate whether genetic polymorphisms of PAI-1 and PAR-1 were predictors of radiation-induced injury in patients with rectal cancer, we retrospectively evaluated 356 rectal cancer patients who had received pelvic radiotherapy and analyzed the association of genetic polymorphisms of PAI-1 and PAR-1 with acute toxicities after radiotherapy. Acute adverse events were scored, including dermatitis, fecal incontinence (anal toxicity), hematological toxicity, diarrhea, and vomiting. The patients were grouped into grade ≥2 and grade 0–1 toxicity groups to analyze the acute toxicities. Genotyping of six single nucleotide polymorphisms (SNPs) of PAI-1 and PAR-1 was performed using TaqMan assays. A logistic regression model was used to estimate the odds ratios and 95% confidence intervals. Of the 356 individuals, 264 (72.5%) had grade ≥2 total toxicities; within this group, there were 65 (18.3%) individuals who reached grade ≥3 toxicities. There were 19.5% (69/354) and 36.9% (130/352) patients that developed grade ≥2 toxicities for diarrhea and fecal incontinence, respectively. The variant genotype GG of rs1050955 in PAI-1 was found to be negatively associated with the risk of diarrhea and incontinence (P <0.05), whereas the AG and GG genotypes of rs2227631 in PAI-1 were associated with an increased risk of incontinence. The CT genotype of PAR-1 rs32934 was associated with an increased risk of total toxicity compared with the CC allele. Our results demonstrated that SNPs in the PAI-1 and PAR-1 genes were associated with acute injury in rectal cancer patients treated with pelvic irradiation. These SNPs may be useful biomarkers for predicting acute radiotoxicity in patients with rectal cancer if validated in future studies.
Keywords: rectal cancer, pelvic radiotherapy, polymorphism, acute toxicity, biomarker


Download Article[PDF]